36 results about "Endothelial cell apoptosis" patented technology

The invention discloses a multifunctional cardiovascular coating material with super-hydraulic performance and a preparation method thereof. The method comprises the following steps that (1) a substrate material is subjected to pretreatment; (2) the pretreated substrate material is put into a buffer system; then, a polyphenol compound and dopamine are added; reaction is performed for 2h at 4 to 50DEG C; then, sodium periodate is added; reaction is performed at 4 to 50 DEG C; (3) the product obtained in the step (2) is subjected to ultrasonic cleaning by deionized water for 3 to 5 times; nitrogen gas is used for drying; the multifunctional cardiovascular coating material is obtained. A prepared multifunctional cardiovascular coating has good stability, excellent hydrophilicity, good anticoagulant performance, good anti-inflammatory performance and good antioxidation performance; the endothelial cell apoptosis is avoided; the capability of inhibiting the smooth muscle cell multiplication is realized; the multifunctional cardiovascular coating material can be used for preparation of blood contact type materials such as intravascular stents, cardiac valves, artificial blood vessels and blood contact catheters in the field of medical materials.

Bioactive peptides that have a molecular weight of approximately 4.5 kDa and correspond to amino-terminal fragments of protease-activated receptor-1 (PAR-1), which are cleaved and released upon the proteolytic activation of PAR-1 by proteases including, but not limited to, thrombin in humans and animals are disclosed. Such synthetic or recombinantly expressed or endogenously produced or chimeric synthetic peptides that are active in vitro and in vivo and modulate endothelial cell functions and physiological and pathological processes are named herein as parstatin. Parstatin peptides, fragments, analogs, derivatives have the ability to inhibit endothelial cell growth, migration and differentiation, to induce endothelial cell apoptosis, to block angiogenesis and have cardioprotective effects in ischemia/reperfusion injury. Methods for treating angiogenesis-related diseases and endothelium dysfunction-related cardiovascular diseases are disclosed.

Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated froms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.

The invention relates to the field of natural drugs and mainly relates to a use of tanshinone IIA derivatives shown in the general formula (I) and the general formula (II) in preparation of a drug for protecting endothelial cells. An experiment result shows that the tanshinone IIA derivatives shown in the general formula (I) and the general formula (II) obviously reduce H2O2-caused endothelial cell damage and reduces H2O2-caused endothelial cell apoptosis. A mechanism research result shows that the tanshinone IIA derivatives shown in the general formula (I) and the general formula (II) produce oxidation resistance through Nrf2-ARE passage activation.

The invention uses cellular apoptosis gene chip in detecting differentia expression of 120 pieces key apoptosis gene regulated and controlled by H2O2 and ophiopogonin D. Research with gene chip technology shows that H2O2 can remarkably up regulate 27 pieces gene and down regulate 3 pieces gene while ophiopogonin D performs antagonism, thereby protecting endothelial cell of blood vessel, which is importance part for preventing and treating cardio-cerebrovascular disorder.

The invention discloses the application of 2, 3-dihydro--3-methylol-6-amino-[1, 4]-benzo-oxazine in preparing medicament for inhibiting blood vessel endothelial cell apoptosis and promoting vascularization. Medicament concentration for effectively inhibiting blood vessel endothelial cell apoptosis caused by sera removing and growth factor is 50-200 mu M.Pharmic concentration for promoting angiogenesis in vitro is 50-100 mu M.Pharmic concentration for promoting angiogenesis in vivo is 200-300 mu M.The inventive 2, 3-dihydro--3-methylol-6-amino-[1, 4]-benzo-oxazine can be used as an effective means for researching molecular mechanism of blood vessel endothelial cell apoptosis vascularization.

The invention discloses a traditional Chinese medicine composition, fermented medicine liquor prepared from the traditional Chinese medicine composition, a preparation method and application. The traditional Chinese medicine composition is prepared from, by weight, 160-480 parts of kudzuvine roots, 80-320 parts of radix salvia miltiorrhiza, 120-400 parts of radix paeoniae alba, 120-400 parts of milkvetch roots, 40-240 parts of rhizoma curcumae longae, 60-280 parts of rhizoma atractylodis macrocephalae, 40-240 parts of semen brassicae, 60-280 parts of fructus crataegi, 60-280 parts of radix bupleuri, 60-280 parts of flos chrysanthemi, 40-240 parts of rhizoma gastrodiae, 60-280 parts of rhizome panacis japonica, 60-280 parts of rhizoma cyperi and 40-240 parts of herba salviae chinensis. Every 1,000 parts by weight of the fermented medicine liquor is prepared by adding and fermenting, by weight, 10-50 parts of saccharomyces cerevisiae, 10-50 parts of bacillus aceticus, 10-50 parts of lactobacillus and the balance traditional Chinese medicine decoction. Experiments show that the fermented medicine liquor has the obvious effect on oxidative stress injuries of cerebral microvascular endothelial cells and can significantly inhibit cerebral microvascular endothelial cell apoptosis and aging which are induced by hydrogen peroxide. Clinical experiments show that the fermented medicine liquor prepared from the traditional Chinese medicine composition can effectively treat ischemic encephalopathy, is safe and effective in treatment, has no adverse influence on the liver and kidney functions of a patient, can be taken for a long term and is worthy of clinical application and popularization.

The invention belongs to the field of pharmaceutical technology. The invention discloses a preparation method and pharmaceutical applications of a phenolic acid compound, namely ethyl rosmarinate. The ethyl rosmarinate is prepared by comprising the following steps: by taking Clinopodium. chinense (Benth.)O. Kuntze whole herb as a raw material, performing grinding, alcohol extraction and reduced pressure recovery to obtain a concentrate, extracting through petroleum ether and ethyl acetate to obtain ethyl acetate extract, and performing repeated column chromatography through macroporous resin, silica gel and MCI. The ethyl rosmarinate has effects of remarkably inhibiting vascular endothelial cell apoptosis induced by high glucose and freefatty acid, improving liver cytolipin consumption under insulin resistance, improving lipid metabolism and inhibiting the activity of alpha-glucosidase. The phenolic acid compound can be used for preparing a medicament for preventing and treating diabetes mellitus, diabetic peripheral vasculopathy, diabetic cardiovascular complications, glucose and lipid metabolism disorders, atherosclerosis, coronary heart diseases and other cardiovascular and cerebrovascular diseases, obesity and fatty liver diseases.

An improved method for treatment of malignancies is based on the interaction between nerve cells and angiogenesis of malignancies. In general, the method comprises: (1) harvesting neural stem cells; (2) culturing neural stem cells under conditions such that the cells proliferate while retaining their ability to differentiate; (3) applying a biocompatible adhesive to a post-surgical site of a malignancy; and (4) following the application of the biocompatible adhesive to the post-surgical site of the malignancy, applying the cultured neural stem cells to the post-surgical site of the malignancy to remove residual tumor cells and to induce endothelial cell apoptosis. The method can further comprise the administration of a therapeutically effective quantity of at least one anti-neoplastic therapeutic agent or administration of a therapeutically effective quantity of anti-neoplastic ionizing radiation. The invention further encompasses kits for use in treating malignancies.

The invention discloses application of interleukin-37b in preparation of a product for preventing and/or treating Kawasaki disease. The product can regulate and control Kawasaki disease coronary artery injury, endothelial cell apoptosis and/or vascular inflammation. The interleukin-37b inhibits endothelial cell apoptosis and vasculitis through IL-1R8 receptor mediated ERK and NF [kappa] B inactivation, so that the Kawasaki disease coronary arteritis is relieved, and finally the purpose of preventing and treating the Kawasaki disease is achieved. Research results show that the interleukin-37b plays an effective role in protecting coronary injury of the Kawasaki disease, and new evidence is provided for using the interleukin-37b as a potential candidate drug for treating the Kawasaki disease.

The invention discloses a novel drug-coated stent and a preparation method thereof. The drug-coated stent comprises a stent and a drug coating coated on the stent; the drug coating is a polymer containing bilirubin or derivatives thereof, and the drug loading capacity of the drug coating of each stent is 140-1700 [mu]g/cm <2>. The invention aims to reduce the occurrence rate of restenosis after formation of intravascular stents such as coronary stents, greatly reduce complications of stent implantation, improve the survival rate and life quality of patients, and reduce the cost of secondary treatment of the patients due to the reduction of the occurrence rate of restenosis. The bilirubin can inhibit vascular smooth muscle proliferation, and can resist endothelial cell apoptosis and angiogenesis. The drug stent can continuously reduce neointima formation and prevent restenosis, meanwhile, the normal endothelialization process is not affected, and the risk of delayed thrombus is avoided.

According to the miRNA marker for cardiovascular disease diagnosis and the application of the miRNA marker, (1) 100mu mol/l Hcy intervenes endothelial cells to establish an apoptosis model, and cell viability staining and flow cytometry are used for detecting that the concentration Hcy can cause endothelial cell apoptosis, so that a foundation is laid for subsequent experiments; (2) after the step (1), the expression level of the miR-491-5p is detected by RT-qPCR (Reverse Transcription-Quantitative Polymerase Chain Reaction); it is determined that miR-491-5p plays a role in endothelial cell apoptosis caused by Hcy; (3) after the miR-491-5p mimics and the miR-491-5p inhibitor are transfected, the expression level of the miR-491-5p is detected through RT-qPCR; after the fact that the miR-491-5p mimics and the miR-491-5p inhibitor are successfully transfected is determined, a foundation is laid for reversely verifying the effect of the miR-491-5p on the endothelial cell apoptosis caused by the Hcy; and (4) miR-491-5p mimics and miR-491-5p inhibitor are respectively transfected, the cell apoptosis condition is detected again by flow cytometry, and it is determined that the miR-491-5p acts on the endothelial cell apoptosis caused by Hcy. The miR-491-5p plays an important role in endothelial cell injury caused by Hcy, the invnetion provides a theoretical basis for detecting and diagnosing atherosclerosis at a molecular level in the future, and has a potential practical value.

The invention discloses an application of scutellarin in preparation of a medicine for preventing and treating atherosclerosis, which belongs to the field of biomedicine and medicines, and discloses an application of scutellarin in preparation of a medicine for preventing and treating atherosclerosis related to a PERK-Nrf2/ATF4-CHOP pathway. The scutellarin is used as a PERK-Nrf2/ATF4-CHOP signal path regulating agent for preventing and treating atherosclerosis. The scutellarin disclosed by the invention can be used for preventing and treating atherosclerosis by resisting endoplasmic reticulum stress and endothelial cell apoptosis, has important significance for clinical treatment of atherosclerosis, and can be used for developing related medicines.

The invention discloses an application of a macrophage migration inhibition factor as a drug target in treatment of perioperative cerebral apoplexy. It is found for the first time that MIF-mediated endothelial cell apoptosis is a main mechanism for destroying blood-brain barrier integrity and neurological impairment after stroke after PIS, and MIF-mediated endothelial cell apoptosis is used as a drug target for treating perioperative cerebral stroke. The invention discloses a mechanism of BBB damage after cerebral apoplexy in the perioperative period and the relation between the mechanism andperipheral immune response for the first time, an innovative mechanism is found for neurological function damage of cerebral arterial thrombosis in the perioperative period, and an innovative treatment thought is provided for improving the neurobehavioral function and cognitive function of cerebral apoplexy in the perioperative period.

The invention discloses applications of a calpain inhibitor in preparing drugs for treating acute kidney injury caused by endotoxin. In applications, the calpain inhibitor can protect acute kidney injury caused by endotoxin by inhibiting endothelial cell calpain. Through the using of the calpain inhibitor and the combined using of multiple cell-specific calpain knockout mice, the effects and possible mechanism of action of the endothelial cell calpain in the acute kidney injury can be researched, and the possibility of taking the calpain inhibitor III as a treatment option can be researched aswell; and after the calpain inhibitor is applied to inhibit the activity of the calpain, p38 phosphorylation can be inhibited so as to reduce iNOS expression and the generation of NO and ROS, and endothelial cell apoptosis can also be inhibited so as to achieve protective effects in the renal injury caused by LPS.

The invention relates to application of epalrestat in preparation of a medicine for preventing and treating cerebral arterial thrombosis (cerebral infarction), and belongs to the technical field of medicines. The invention provides application of epalrestat in preparation of the medicine for preventing and treating cerebral arterial thrombosis for cerebral arterial thrombosis patients who have missed a treatment time window and cannot be treated by thrombolysis in the early stage of cerebral arterial thrombosis. Epalrestat is used for treatment after cerebral arterial thrombosis, expression of aldose reductase can be inhibited, tight junction protein of cerebral microvascular endothelial cells can be up-regulated, endothelial cell apoptosis can be relieved, neurological dysfunction after cerebral arterial thrombosis can be improved, and integrity of blood-brain barrier after cerebral arterial thrombosis can be maintained; in addition, epalrestat can effectively reduce infiltration of peripheral inflammatory cells and relieve inflammatory response in ischemic brain tissue. The invention provides a new effective way for preventing and treating cerebral arterial thrombosis, and provides a theoretical basis for treating clinical cerebral arterial thrombosis by epalrestat.

The invention discloses an application of a P110 delta mutational inactivated mouse model, which comprises application of P110 delta mutational inactivated mouse in research of aneurysm occurrence mechanism and/or screening drugs for treating aneurysm. According to the application provided by the invention, tectology and molecular biology methods are symmetrically adopted to determine the vascular wall of the P110 delta mutational inactivated mouse has certain pathological damage, which is mainly characterized by endothelial cells apoptosis, smooth muscle cell decrease and collagen and elastic fiber ingredient reduction, and the raise of the cell factors and the damage characteristics of the vascular wall are very close to the typical characteristics of aneurysm, so that the P110 delta mutational inactivated mouse can be used as an ideal model for the research of initial stage drug target and mechanism of the aneurysm.